The Center for Biosimilars® recaps the top stories for the week of July 29, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 29, 2019.
Number 5: A proposed amendment to the Biologics Price Competition and Innovation Act would require that the FDA continue to review insulins submitted as drugs even after the March 2020 transition of insulins to regulation as biologics.
Number 4: Amgen lost its fight to block Coherus BioSciences from selling its biosimilar pegfilgrastim.
Number 3: In the United States, Humira sales grew by $3.8 billion last quarter, up 7.7% from the prior year.
Number 2: Pfizer’s off-patent drug unit, Upjohn, and Mylan have announced a deal under which they will combine to form a new company that will have expanded reach.
Number 1: The Federal Trade Commission issued civil subpoenas to Johnson & Johnson as part of an antitrust investigation into its strategy to defend sales of its innovator infliximab against biosimilar competition.
Finally, last week, our e-newsletter asked whether you think that the price discounts offered on Amgen’s 2 newly launched anticancer biosimilars are enough to spur US uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.